Status:
SUSPENDED
Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)
Lead Sponsor:
Cedars-Sinai Medical Center
Conditions:
PDAC - Pancreatic Ductal Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI) is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC).
Detailed Description
The overarching goal of this pilot study is to evaluate the usefulness of a novel Magnetic Resonance Imaging (MRI) approach, which measure properties of tumor microenvironment (i.e. vascularity, fibro...
Eligibility Criteria
Inclusion
- Pancreatic cancer patients (with resectable or borderline resectable or locally advanced tumors) who will undergo neoadjuvant chemotherapy
- Patients able to undergo at least two sets of MRI sessions
Exclusion
- Patients who have previously been treated for PDAC
- Patients unable to undergo MRI exam w/contrast
- Patients with metastatic pancreatic cancer visualized on index diagnostic imaging
- Patients with certain metallic implants
- Patients experiencing claustrophobia
- Persons with allergy to animal dander or animal-instigated asthma
Key Trial Info
Start Date :
May 19 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04700488
Start Date
May 19 2022
End Date
January 1 2026
Last Update
December 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048